Clinical Trials on HPV-Related Squamous Cell Carcinoma in United Kingdom

Total 9057 results

M.D. Anderson Cancer Center
Astellas Pharma Inc; The Kadoorie Charitable Foundations

Recruiting

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Head and Neck Cancer

United States
University of Miami

Completed

Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
Julie E. Bauman, MD, MPH
Novartis

Terminated

Phase II Study of RAD001 Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
University of Tennessee Cancer Institute
National Comprehensive Cancer Network

Terminated

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Dana-Farber Cancer Institute

Recruiting

Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

Head and Neck Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

Malignant Solid Neoplasm | Head and Neck Squamous Cell Carcinoma

United States
SecuraBio

Terminated

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
University of Cincinnati

Completed

Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Southern Illinois University
Genentech, Inc.; OSI Pharmaceuticals

Completed

Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

Head and Neck Cancer

United States
University of Colorado, Denver
Vasgene Therapeutics, Inc

Completed

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Squamous Cell Carcinoma of Head and Neck

United States
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Belgium, Australia, United States
RTOG Foundation, Inc.
Bristol-Myers Squibb

Completed

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma

Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Laryngeal Squamous Cell Carcinoma AJCC... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Completed

Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma

HEAD & NECK Cancer

United States
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

United States
Heath Skinner

Completed

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Squamous Cell Carcinoma of the Head and Neck Cancer | Previously-Irradiated

United States
Meharry Medical College

Recruiting

A Tailored, Health Communication Intervention for HPV Vaccine Hesitant Families

Parents | HPV-Related Carcinoma | Human Papilloma Virus | Vaccine Refusal | Program, Communication

United States
National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
University of Arkansas

Active, not recruiting

Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC

Squamous Cell Carcinoma of the Head and Neck

United States
University of Arkansas

Withdrawn

A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)

Squamous Cell Carcinoma of the Head and Neck

United States
University of Arkansas
Erasmus Medical Center; The Netherlands Cancer Institute; Biolitec Pharma Ltd.

Terminated

Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers

Squamous Cell Carcinoma of the Head and Neck

United States
Marcelo Bonomi

Recruiting

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditions

United States
Washington University School of Medicine
Eli Lilly and Company

Terminated

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Head and Neck Squamous Cell Carcinoma

United States
The University of Texas Health Science Center at...
University of Pittsburgh

Completed

Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma

United States
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Active, not recruiting

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
University of Chicago
AstraZeneca

Completed

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma

United States
Vanderbilt-Ingram Cancer Center
American Cancer Society, Inc.

Recruiting

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma

United States
Rowan University
Rutgers University

Recruiting

Using MASL to Combat Oral Cancer

Squamous Cell Carcinoma of Head and Neck

United States
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Head and Neck Squamous Cell Carcinoma

Germany, United Kingdom, United States, Spain, Italy, Canada, Poland, Russian Federation, Switzerland, Thailand, Korea, Republic of, Hungary, Ireland, Australia, Taiwan, France, India, Japan
Dana-Farber Cancer Institute
Massachusetts General Hospital; Sanofi; Beth Israel Deaconess Medical Center; Brigham...

Completed

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma | Carcinoma of Head and/or Neck

United States
Presage Biosciences
Takeda

Completed

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Recruiting

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Lynn Cancer Institute

Active, not recruiting

Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma

Squamous Cell Carcinoma | Cutaneous Basal Cell

United States
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
University of Florida

Withdrawn

Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx

Advanced Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oral Cavity Squamous Cell Carcinoma... and other conditions

United States
Presage Biosciences
AstraZeneca

Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Institutes of Health (NIH); Tvardi Therapeutics, Inc

Not yet recruiting

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of Head and Neck

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditions

United States
Fox Chase Cancer Center

Terminated

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
European Organisation for Research and Treatment...

Recruiting

Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma (Best Of)

Oropharyngeal Cancer | Hypopharyngeal Squamous Cell Carcinoma | Supraglottic Squamous Cell Carcinoma

Spain, Belgium, Switzerland, Italy, United Kingdom, Germany, France, Poland
University of Southern California
Sanofi

Terminated

Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck

Carcinoma of the Head and Neck

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Second Primary Squamous Cell Carcinoma of the Head and Neck

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

HEAD & NECK Cancer

United States
Dana-Farber Cancer Institute

Terminated

Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

Squamous Cell Carcinoma of the Head and Neck | Human Papilloma Virus

United States
University of Maryland, Baltimore

Active, not recruiting

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma

United States
University of Chicago
Celgene Corporation

Completed

Cetuximab and Lenalidomide in Head and Neck

Squamous Cell Carcinoma

United States
Inhibrx, Inc.

Recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
University of Cincinnati

Completed

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States

Clinical Trials on HPV-Related Squamous Cell Carcinoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations